Guillain-Barré syndrome after simultaneous therapy with suramin and interferon-alpha [1]

European Journal of Neurology

Volumn 10, Issue 5, 2003, Pages 599-

  Bachmann, T ^a,b,d   Koetter, K P ^b,c   Muhler J ^b   Fuhrmeister, U ^b   Seidel, G ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Leopoldina Krankenhaus   (Germany)

^c KLINIKUM ASCHAFFENBURG   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Guillain Barr Syndrome; Interferon alpha; Suramin

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SURAMIN;

ADULT; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BLOOD TOXICITY; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; FLACCID PARALYSIS; GUILLAIN BARRE SYNDROME; HUMAN; LETTER; LUNG ADENOCARCINOMA; MUSCLE ATROPHY; MYASTHENIA GRAVIS; NEUROPATHY; NEUROTOXICITY; PRIORITY JOURNAL; QUADRIPLEGIA; VIRUS HEPATITIS; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; INTERFERON-ALPHA; SURAMIN;

EID: 0345802807     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2003.00653.x     Document Type: Letter

References (13)

1. Baron S, Tyring SK, Fleischmann WR et al. (1991). The interferons: mechanism of action and clinical application. JAMA 266:1375-1383.
2. Batocchi AP, Evoli A, Servidei S, Palmisani MT, Apollo F, Tonali P (1995). Myasthenia gravis during interferon alfa therapy. Neurology 45:382-383.
3. Bernsen PLJA, Wong-Chung RE, Vingerhoets HM, Janssen JTP (1988). Bilateral neuralgic amyotrophy induced by interferon treatment. Arch Neurol 45:449-451.
4. Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR (1996). A prospective study of suramin-induced peripheral neuropathy. Brain 119:2039-2052.
5. La Civita L, Zignego AL, Lombardini F et al. (1996). Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and Hepatitis B virus infection. J Rheumatol 23:1641-1643.
6. LaRocca RV, Meer J, Gilliatt RW et al. (1990). Suramin-induced polyneuropathy. Neurology 40:954-960.
7. Ropper AJ (1992). The Guillain-Barré Syndrome. N Engl J Med 326:1130-1136.
8. Rutkove SB (1997). An unusual axonal polyneuropathy induced by low-dose interferon alfa-2a. Arch Neurol 54:907-908.
9. Schwarzer A, Schulze E, Leiblein S et al. (1995). Guillain Barré syndrome, a possible side effect of buffy coat transfusion and IFN α therapy in relapsed CML after bone marrow transplantation. Ann Oncol 6:617-619.
10. Soliven B, Dhand UK, Kobayashi K et al. (1997). Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve 20:83-91.
11. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE (1989). Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-508.
12. Vial T, Descotes J (1994). Clinical toxicity of the interferones. Drug Safety 10:115-150.
13. Weinstock-Guttmann B, Ransohoff RM, Kinkel RP, Rudick RA (1995). The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 37:7-15.